BRIACELL THERAPEUTICS CORP. Increase (Decrease) in Accounts Receivable
BRIACELL THERAPEUTICS CORP. (BCTX) reported Increase (Decrease) in Accounts Receivable of -$733.63 thousand for the 12-month period ending 2025-07-31, per its 10-K filed 2025-10-16.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-10-16
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for the quarter ending 2025-07-31 was -$514.00, a 100.07% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for the quarter ending 2025-04-30 was -$9.94K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for the quarter ending 2025-01-31 was $13.62K, a 55.88% increase year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for the quarter ending 2024-10-31 was -$736.79K, a 29141.70% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for fiscal 2025 was -$733.63K, a 200.14% decline from fiscal 2024.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for fiscal 2024 was $732.58K.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for fiscal 2023 was -$5.23K, a 145.36% decline from fiscal 2022.
- BRIACELL THERAPEUTICS CORP. increase (decrease) in accounts receivable for fiscal 2022 was $11.53K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2025-07-31 | -$514.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | -$10.46K derived: sum of 2 quarters · filed 2025-10-16 | $3.16K derived: sum of 3 quarters · filed 2025-10-16 | -$733.63K 10-K · filed 2025-10-16 |
| 2025-04-30 | -$9.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-16 | $3.67K derived: sum of 2 quarters · filed 2025-06-16 | -$733.12K 10-Q · filed 2025-06-16 | $3.10K derived: sum of 4 quarters · filed 2025-10-16 |
| 2025-01-31 | $13.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-12 | -$723.17K 10-Q · filed 2025-03-12 | $13.05K derived: sum of 3 quarters · filed 2025-10-16 | -$1.87K derived: sum of 4 quarters · filed 2025-10-16 |
| 2024-10-31 | -$736.79K 10-Q · filed 2024-12-16 | -$570.00 derived: sum of 2 quarters · filed 2025-10-16 | -$15.48K derived: sum of 3 quarters · filed 2025-10-16 | -$6.75K derived: sum of 4 quarters · filed 2025-10-16 |
| 2024-07-31 | $736.22K derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $721.31K derived: sum of 2 quarters · filed 2025-10-16 | $730.04K derived: sum of 3 quarters · filed 2025-10-16 | $732.58K 10-K · filed 2025-10-16 |
| 2024-04-30 | -$14.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-16 | -$6.18K derived: sum of 2 quarters · filed 2025-06-16 | -$3.64K 10-Q · filed 2025-06-16 | $337.00 derived: sum of 4 quarters · filed 2025-06-16 |
| 2024-01-31 | $8.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-03-12 | $11.27K 10-Q · filed 2025-03-12 | $15.25K derived: sum of 3 quarters · filed 2025-03-12 | $21.22K derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-10-31 | $2.54K 10-Q · filed 2024-12-16 | $6.51K derived: sum of 2 quarters · filed 2024-12-16 | $12.48K derived: sum of 3 quarters · filed 2024-12-16 | -$8.29K derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $3.98K derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $9.95K derived: sum of 2 quarters · filed 2024-10-29 | -$10.82K derived: sum of 3 quarters · filed 2024-10-29 | -$5.23K 10-K · filed 2024-10-29 |
| 2023-04-30 | $5.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | -$14.80K derived: sum of 2 quarters · filed 2024-06-14 | -$9.21K 10-Q · filed 2024-06-14 | $365.00 derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | -$20.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-18 | -$15.18K 10-Q · filed 2024-03-18 | -$5.60K derived: sum of 3 quarters · filed 2024-03-18 | -$18.24K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | $5.59K 10-Q · filed 2023-12-14 | $15.17K derived: sum of 2 quarters · filed 2023-12-14 | $2.53K derived: sum of 3 quarters · filed 2023-12-14 | $10.37K derived: sum of 4 quarters · filed 2023-12-14 |
| 2022-07-31 | $9.57K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | -$3.06K derived: sum of 2 quarters · filed 2023-10-25 | $4.78K derived: sum of 3 quarters · filed 2023-10-25 | $11.53K 10-K · filed 2023-10-25 |
| 2022-04-30 | -$12.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | -$4.80K derived: sum of 2 quarters · filed 2023-06-14 | $1.96K 10-Q · filed 2023-06-14 | |
| 2022-01-31 | $7.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-16 | $14.59K 10-Q · filed 2023-03-16 | ||
| 2021-10-31 | $6.75K 10-Q · filed 2022-12-14 | |||
| 2021-07-31 | -$9.94K 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |